Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVN NASDAQ:INSM NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$15.31+2.4%$10.78$7.48▼$18.57$2.25B1.353.53 million shs6.06 million shsINSMInsmed$104.47+1.0%$113.76$90.39▼$212.75$22.43B0.794.76 million shs4.41 million shsQUREuniQure$49.10+0.5%$27.23$8.73▼$71.50$3.08B0.982.82 million shs2.92 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven+2.65%+12.90%+52.66%+82.31%+6.78%INSMInsmed+0.99%+9.17%-4.04%-28.10%-0.36%QUREuniQure+0.51%+6.07%+95.23%+232.43%+242.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$15.31+2.4%$10.78$7.48▼$18.57$2.25B1.353.53 million shs6.06 million shsINSMInsmed$104.47+1.0%$113.76$90.39▼$212.75$22.43B0.794.76 million shs4.41 million shsQUREuniQure$49.10+0.5%$27.23$8.73▼$71.50$3.08B0.982.82 million shs2.92 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven+2.65%+12.90%+52.66%+82.31%+6.78%INSMInsmed+0.99%+9.17%-4.04%-28.10%-0.36%QUREuniQure+0.51%+6.07%+95.23%+232.43%+242.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 2.71Moderate Buy$22.2745.42% UpsideINSMInsmed 2.96Moderate Buy$211.86102.80% UpsideQUREuniQure 2.65Moderate Buy$61.6725.59% UpsideCurrent Analyst Ratings BreakdownLatest BHVN, INSM, and QURE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026QUREuniQure MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $68.006/18/2026QUREuniQure Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $65.006/18/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/18/2026QUREuniQure Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $70.006/18/2026QUREuniQure The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$14.00 ➝ $46.006/18/2026QUREuniQure BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$25.00 ➝ $65.006/17/2026QUREuniQure BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingPositive6/17/2026QUREuniQure Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$61.006/16/2026INSMInsmed MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$192.006/10/2026INSMInsmed Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/8/2026INSMInsmed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$0.39 per shareN/AINSMInsmed$606.42M37.34N/AN/A$3.46 per share30.19QUREuniQure$16.10M192.34N/AN/A$3.19 per share15.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%8/10/2026 (Estimated)INSMInsmed-$1.28B-$5.75N/A128.98N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)QUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%8/4/2026 (Estimated)Latest BHVN, INSM, and QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026INSMInsmed-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 million5/4/2026Q1 2026BHVNBiohaven-$0.86-$0.88-$0.02-$0.88$0.27 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohaven1.877.417.41INSMInsmed0.804.474.10QUREuniQure0.3310.4010.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%INSMInsmedN/AQUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipBHVNBiohaven13.80%INSMInsmed2.10%QUREuniQure4.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239150.56 million129.78 millionOptionableINSMInsmed1,664216.75 million212.20 millionOptionableQUREuniQure50063.07 million60.13 millionOptionableBHVN, INSM, and QURE HeadlinesRecent News About These CompaniesuniQure Closes $259 Million Public Offering of Ordinary SharesJune 25 at 4:30 PM | quiverquant.comQuniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesJune 25 at 4:10 PM | globenewswire.comUniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program AdvancesJune 25 at 1:35 PM | finance.yahoo.comuniQure Completes Upsized Public Equity Offering for GrowthJune 24 at 5:30 PM | tipranks.comuniQure N.V. (QURE) Stock Dips Following $225M Share Offering AnnouncementJune 24 at 11:31 AM | blockonomi.comuniQure Announces Pricing of $225 Million Public Offering of Ordinary SharesJune 23 at 9:31 PM | quiverquant.comQuniQure Announces Pricing of Upsized $225 Million Public OfferingJune 23 at 9:13 PM | globenewswire.comuniQure (NASDAQ:QURE) Trading Up 8.3% - Here's WhyJune 23 at 11:59 AM | marketbeat.comuniQure (NASDAQ:QURE) Director Jack Kaye Sells 5,295 Shares of StockJune 23 at 5:32 AM | americanbankingnews.comuniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 41,671 SharesJune 23 at 4:59 AM | americanbankingnews.comuniQure (NASDAQ:QURE) Director Madhavan Balachandran Sells 11,685 Shares of StockJune 23 at 4:59 AM | americanbankingnews.comInsider Selling: uniQure (NASDAQ:QURE) Director Sells 5,295 SharesJune 23 at 4:21 AM | insidertrades.comuniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 164,429 SharesJune 23 at 4:09 AM | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), uniQure (QURE)June 23 at 1:59 AM | theglobeandmail.comuniQure Announces $150 Million Proposed Public OfferingJune 22, 2026 | globenewswire.comUniQure's experimental drug shows early promise in difficult-to-treat epilepsyJune 22, 2026 | msn.comuniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat EpilepsyJune 22, 2026 | benzinga.comQURE Announces Initial Data on Gene therapy for Temporal Lobe EpilepsyJune 22, 2026 | zacks.comuniQure announces preliminary data on first cohort in Phase I/IIa clinical trial of AMT-260June 22, 2026 | pharmabiz.comPuniQure Announces Promising Early Data for AMT-260June 22, 2026 | tipranks.comUniQure to seek approval of Huntington’s gene therapy after FDA U-turnJune 20, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHVN, INSM, and QURE Company DescriptionsBiohaven NYSE:BHVN$15.31 +0.35 (+2.35%) Closing price 06/25/2026 03:59 PM EasternExtended Trading$15.37 +0.06 (+0.37%) As of 06/25/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Insmed NASDAQ:INSM$104.47 +1.01 (+0.98%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$105.87 +1.40 (+1.34%) As of 06/25/2026 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.uniQure NASDAQ:QURE$49.10 +0.25 (+0.51%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$49.46 +0.36 (+0.73%) As of 06/25/2026 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal MDA Space Targets US Defense Market With $620M Acquisition Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software Moat Cerebras Systems, Inc: The Next Rags-to-Riches AI Story? Domino's Stock Slides to 52-Week Low as Investors Digest CEO Change Getty Images’ OpenAI Deal Gives the Stock a New AI Licensing Story Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
